Article: article from journal or magazin.
Apport des modèles expérimentaux: associations Synercid et beta-lactamines
25 Pt 2
SYNERCID ALONE IN A RAT MODEL OF EXPERIMENTAL ENDOCARDITIS: Trials conducted using 2 injections daily showed that animals infected with meti-R resistant Staphylococcus aureus strains sensitive to erythromycin were cured in 3 days. The same is not true for infections caused by C-MLSB-R staphylococci. The daily dose cannot be increased due to the venous toxicity of Synercid, leading to the idea of testing Synercid in combination with other antibiotics. IN VITRO STUDIES: Several antibiotics have been tested in combination with Synercid. Several beta-lactams have been shown to exhibit an additive or synergetic effect on a collection of meti-R and meti-S S. aureus strains. IN VIVO STUDIES: In animals infected with C-MLSB-R meti-R S. aureus, the combination Synercid + cefepime increases the activity of cefipime and prevents selection of beta-lactam highly resistant strains. The results obtained with the Synercid + cefpirome combination are even more eloquent. Finally, Synercid, alone or in combination with these 2 cephalosporins, does not select resistant strains.
Animals, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/adverse effects, Drug Synergism, Drug Therapy, Combination/adverse effects, Drug Therapy, Combination/therapeutic use, Endocarditis, Bacterial/drug therapy, Humans, Rats, Staphylococcal Infections/drug therapy, Virginiamycin/administration & dosage, Virginiamycin/adverse effects, beta-Lactams
Web of science
Last modification date